S2616
Radiobiology - Translational radiobiology
ESTRO 2026
Conclusion: A genome-wide CVD-derived expression score is prognostic in thoracic but not in non-thoracic cancers. These findings indicate an anatomic site–specific effect in cancer populations treated with cardiac-adjacent radiotherapy and/or anthracyclines. Further assessment in cohorts with treatment-specific and cause of death data and/or cardiac imaging is warranted to determine potential clinical relevance. References: [1] Khera AV, Chaffin M, Aragam KG, et al. Genome- wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018 Sep;50(9):1219-1224. doi: 10.1038/s41588-018-0183-z. Epub 2018 Aug 13. PMID: 30104762; PMCID: PMC6128408.[2] K. Watanabe, E. Taskesen, A. van Bochoven and D. Posthuma. Functional mapping and annotation of genetic associations with FUMA. Nat. Commun. 8:1826. (2017).https://www.nature.com/articles/s41467-017- 01261-5 Keywords: Cardio-oncology, Genomics, Survivorship dynamic interplay between gut microbiota and metabolism during immunotherapy-based total neoadjuvant therapy in early low rectal cancer Mingxu Yan 1 , Yajie Chen 1 , Yaqi Wang 1 , Hui Zhang 1 , Juefeng Wan 1 , Lijun Shen 1 , Yan Wang 1 , Wang Yang 1 , Menglong Zhou 1 , Ruiyan Wu 1 , Shujuan Zhou 1 , Jinluan Li 2 , Sanjun Cai 3 , Fan Xia 1 , Xinxiang Li 3 , Zhen Zhang 1 1 Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. 2 Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. 3 Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China Digital Poster Highlight 1480
Results: Higher CVDz scores were associated with reduced survival in thoracic malignancies (Figure 2A). The entire thoracic cohort showed HR=1.15 (95% CI 1.06–1.25; p=0.0006; n=543 deaths). In breast cancer (n=151 deaths), HR=1.48 (95% CI 1.25–1.74; p=3.09 × 10 ⁻ ⁶ ), with left-sided HR=1.49 (95% CI 1.04–2.13; p=0.003) and right-sided HR=1.41 (95% CI 1.14–1.74; p=0.002). Lung squamous carcinoma (n=212 deaths) showed HR=1.16 (95% CI 1.03–1.32; p=0.020), while lung adenocarcinoma (n=180 deaths) showed no association (HR=0.95; 95% CI 0.81–1.12; p=0.54). Restricted cubic splines showed a continuous, approximately linear score–survival association (Figures 2B-C). Non-thoracic cancers showed no association between higher CVDz score and survival (pooled HR=1.05; 95% CI 0.97–1.13; p=0.22). External datasets reproduced the thoracic patterns: anthracycline-treated breast cancer (GSE25066, HR=1.29; 95% CI 1.09–1.53;p=0.030) and early-stage lung adenocarcinoma (GSE31210, HR=0.64; 95% CI 0.40–1.01;p=0.053).
Purpose/Objective: As a prospective phase II trial, TORCH-E (NCT05555888) demonstrated that the
immunotherapy-based total neoadjuvant therapy (iTNT) regimen, comprising short-course radiotherapy (SCRT) followed by CAPOX and Toripalimab, could enhance tumor regression and organ preservation rates in patients with early low rectal cancer. This study aimed to decipher the dynamics of gut microbiota during iTNT treatment and explore potential biomarkers associated with treatment response. Material/Methods: We prospectively collected 160 fecal samples from 26 patients in the TORCH-E trial at four time points: baseline, post SCRT, post-2 cycles of immunochemotherapy, and post-4 cycles of
Made with FlippingBook - Share PDF online